{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:16Z","timestamp":1783617376522,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40121-026-01373-w","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:20:39Z","timestamp":1781187639000},"page":"2103-2119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-3711","authenticated-orcid":false,"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-3766","authenticated-orcid":false,"given":"J\u00falia","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-829X","authenticated-orcid":false,"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0035-4574","authenticated-orcid":false,"given":"Maite","family":"Le\u00f3n-Fabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-4101","authenticated-orcid":false,"given":"Maria","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-246X","authenticated-orcid":false,"given":"Ivan","family":"Chivite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-3457","authenticated-orcid":false,"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Arreba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-6686","authenticated-orcid":false,"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-5206","authenticated-orcid":false,"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Callau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-3186","authenticated-orcid":false,"given":"Alberto","family":"Foncillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3347-9383","authenticated-orcid":false,"given":"Abiu","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2010-2744","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-7755","authenticated-orcid":false,"given":"Jose M.","family":"Miro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Llobet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-141X","authenticated-orcid":false,"given":"Josep","family":"Mallolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-6352","authenticated-orcid":false,"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"4","key":"1373_CR1","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","volume":"8","author":"C Orkin","year":"2021","unstructured":"Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase\u00a03 FLAIR study. Lancet HIV. 2021;8(4):e185\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(20)30340-4.","journal-title":"Lancet HIV"},{"key":"1373_CR2","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2020","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2\u00a0months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase\u00a03b, non-inferiority study. Lancet. 2020;396:1994\u20132005. https:\/\/doi.org\/10.1016\/S0140-6736(20)32666-0.","journal-title":"Lancet"},{"issue":"9","key":"1373_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/CID\/CIAD020","volume":"76","author":"ET Overton","year":"2023","unstructured":"Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type\u00a01 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase\u00a03b, noninferiority study. Clin Infect Dis. 2023;76(9):1646\u201354. https:\/\/doi.org\/10.1093\/CID\/CIAD020.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1373_CR4","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/JAC\/DKAF184","volume":"80","author":"R Gagliardini","year":"2025","unstructured":"Gagliardini R, De Benedittis S, Tavelli A, et al. Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir\/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. J Antimicrob Chemother. 2025;80(8):2169\u201378. https:\/\/doi.org\/10.1093\/JAC\/DKAF184.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1373_CR5","doi-asserted-by":"publisher","first-page":"ofae326","DOI":"10.1093\/OFID\/OFAE326","volume":"11","author":"C Muccini","year":"2024","unstructured":"Muccini C, Gianotti N, Diotallevi S, et al. One year of long-acting cabotegravir and rilpivirine in people with human immunodeficiency virus and long exposure to antiretroviral therapy: data from the SCohoLART study. Open Forum Infect Dis. 2024;11(7):ofae326. https:\/\/doi.org\/10.1093\/OFID\/OFAE326.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"1373_CR6","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1093\/jac\/dkaf389","volume":"80","author":"L Buz\u00f3n-Mart\u00edn","year":"2025","unstructured":"Buz\u00f3n-Mart\u00edn L, Luisa Montes M, Pedrero R, et al. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). J Antimicrob Chemother. 2025;80(12):3438\u201351. https:\/\/doi.org\/10.1093\/jac\/dkaf389.","journal-title":"J Antimicrob Chemother"},{"key":"1373_CR7","unstructured":"Gonz\u00e1lez-Cord\u00f3n A, Torres B, Berrocal L, et al. Long-acting cabotegravir\/rilpivirine in real life: sex-based characteristics, PROs, and effectiveness [CROI Abstract 678]. In Special Issue: Abstracts from the CROI 2025 Conference on Retroviruses and Opportunistic Infections.Top Antivir Med. 2025;33(1):190."},{"issue":"4","key":"1373_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/jac\/dkaf038","volume":"80","author":"M Rosas Cancio-Su\u00e1rez","year":"2025","unstructured":"Rosas Cancio-Su\u00e1rez M, Moreno A, Del Campo TS, et al. Real-world efficacy and tolerability of CAB+RPV LA in women: addressing the gender gap in HIV treatment research. J Antimicrob Chemother. 2025;80(4):1084\u20138. https:\/\/doi.org\/10.1093\/jac\/dkaf038.","journal-title":"J Antimicrob Chemother"},{"key":"1373_CR9","unstructured":"Altamirano J, Levis B, Markarian C, et al. Clinical outcomes among virologically suppressed women receiving CAB+RPV LA in the OPERA Cohort. Poster [CROI Abstract 676]. In Special Issue: Abstracts from the CROI 2025 Conference on Retroviruses and Opportunistic Infections.Top Antivir Med. 2025;33(1):189."},{"key":"1373_CR10","unstructured":"Galindo Puerto MJ, De Miguel R, Troya Garc\u00eda J, et al. Efficacy and safety of long-acting intramuscular cabotegravir and rilpivirine inwomen: a substudy of the RELATIVITY cohort [Abstract RO3.7]. In: Abstracts of the 20th European AIDS Conference 2025, October 15\u201318, 2025, Paris, France. HIV Med. 2025 Oct;26 Suppl 4:115."},{"issue":"6","key":"1373_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/QAD.0000000000003478","volume":"37","author":"S Zhou","year":"2023","unstructured":"Zhou S, Qi K, Nugent BM, Bersoff-Matcha SJ, Struble K. Participation of HIV-1 infected treatment-naive females in clinical trials and sex differences in efficacy and safety outcomes. AIDS Lond Engl. 2023;37(6):895\u2013903. https:\/\/doi.org\/10.1097\/QAD.0000000000003478.","journal-title":"AIDS Lond Engl"},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","volume":"14","author":"V Chounta","year":"2021","unstructured":"Chounta V, Overton ET, Mills A, et al. Patient-reported outcomes through 1\u00a0year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8\u00a0weeks (ATLAS-2M). Patient. 2021;14:849\u201362. https:\/\/doi.org\/10.1007\/s40271-021-00524-0.","journal-title":"Patient"},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24:3533\u201344. https:\/\/doi.org\/10.1007\/s10461-020-02929-8.","journal-title":"AIDS Behav"},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10461-024-04490-0","volume":"29","author":"C Mussini","year":"2025","unstructured":"Mussini C, Cazanave C, Adachi E, et al. Improvements in patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir\/emtricitabine\/tenofovir alafenamide in the phase\u00a03b SOLAR Study. AIDS Behav. 2025;29:64\u201376. https:\/\/doi.org\/10.1007\/s10461-024-04490-0.","journal-title":"AIDS Behav"},{"issue":"1","key":"1373_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12955-018-0962-3","volume":"16","author":"J Lambert","year":"2018","unstructured":"Lambert J, Chekroun M, Gilet H, Acquadro C, Arnould B. Assessing patients\u2019 acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community. Health Qual Life Outcomes. 2018;16(1):1\u20139. https:\/\/doi.org\/10.1186\/S12955-018-0962-3.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"1373_CR16","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1007\/S12325-023-02656-1","volume":"40","author":"V Chounta","year":"2023","unstructured":"Chounta V, Byrnes HF, Henry-Szatkowski M, Browning D, Donatti C, Lambert J. Psychometric validation of the Perception of Injection (PIN) Questionnaire using data from two phase\u00a0III, open-label, active-controlled, non-inferiority studies in people living with HIV. Adv Ther. 2023;40(12):5300\u201314. https:\/\/doi.org\/10.1007\/S12325-023-02656-1.","journal-title":"Adv Ther"},{"issue":"6","key":"1373_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1023\/A:1018464200708","volume":"6","author":"WC Holmes","year":"1997","unstructured":"Holmes WC, Shea JA. Performance of a new, HIV\/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals. Qual Life Res. 1997;6(6):561\u201371. https:\/\/doi.org\/10.1023\/A:1018464200708.","journal-title":"Qual Life Res"},{"key":"1373_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25902","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, He C, Peasgood T, et al. Use of quality-of-life instruments for people living with HIV: a global systematic review and meta-analysis. J Int AIDS Soc. 2022;2022:25902. https:\/\/doi.org\/10.1002\/jia2.25902.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"1373_CR19","doi-asserted-by":"publisher","first-page":"e649","DOI":"10.1016\/S2352-3018(25)00131-6","volume":"12","author":"C Orkin","year":"2025","unstructured":"Orkin C, Paterson A, Elias A, et al. Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process. Lancet HIV. 2025;12(9):e649\u201359. https:\/\/doi.org\/10.1016\/S2352-3018(25)00131-6.","journal-title":"Lancet HIV"},{"issue":"2","key":"1373_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"1373_CR21","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"key":"1373_CR22","volume-title":"Stata statistical software: release 19","author":"StataCorp","year":"2025","unstructured":"StataCorp. Stata statistical software: release 19. College Station, TX: StataCorp LLC; 2025."},{"key":"1373_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/CIAG023","author":"A Foncillas","year":"2026","unstructured":"Foncillas A, Ambrosioni J, Sempere A, et al. Hepatitis\u00a0B outcomes after switching to long-acting cabotegravir\/rilpivirine in people with HIV: reactivation, incident infection, and liver safety across diverse serological profiles. Clin Infect Dis. 2026. https:\/\/doi.org\/10.1093\/CID\/CIAG023.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1373_CR24","doi-asserted-by":"publisher","first-page":"e0005222","DOI":"10.1128\/CMR.00052-22","volume":"35","author":"C Chu","year":"2022","unstructured":"Chu C, Armenia D, Walworth C, Santoro MM, Shafer RW. Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells. Clin Microbiol Rev. 2022;35(4):e0005222. https:\/\/doi.org\/10.1128\/CMR.00052-22.","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"1373_CR25","doi-asserted-by":"publisher","first-page":"2200317","DOI":"10.2807\/1560-7917.ES.2023.28.10.2200317","volume":"28","author":"S Toyos","year":"2023","unstructured":"Toyos S, Berrocal L, Gonz\u00e1lez-Cord\u00f3n A, et al. Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, to 2020. Euro Surveill. 2023;28(10):2200317. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.10.2200317.","journal-title":"Euro Surveill"},{"issue":"3","key":"1373_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092334","volume":"9","author":"A Carter","year":"2014","unstructured":"Carter A, Min JE, Chau W, et al. Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010). PLoS ONE. 2014;9(3):e92334. https:\/\/doi.org\/10.1371\/journal.pone.0092334.","journal-title":"PLoS ONE"},{"issue":"1","key":"1373_CR27","doi-asserted-by":"publisher","first-page":"e26401","DOI":"10.1002\/JIA2.26401","volume":"28","author":"S Delany-Moretlwe","year":"2025","unstructured":"Delany-Moretlwe S, Hanscom B, Guo X, et al. Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084. J Int AIDS Soc. 2025;28(1):e26401. https:\/\/doi.org\/10.1002\/JIA2.26401.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"1373_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cid\/ciae331","volume":"80","author":"LF Collins","year":"2025","unstructured":"Collins LF, Sheth AN, Tisdale T, et al. Interest in and preference for long-acting injectable antiretroviral therapy in the era of approved cabotegravir\/rilpivirine among reproductive-aged women in the US South. Clin Infect Dis. 2025;80(1):164\u20137. https:\/\/doi.org\/10.1093\/cid\/ciae331.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1373_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s10461-021-03483-7","volume":"26","author":"MM Philbin","year":"2022","unstructured":"Philbin MM, Bergen S, Parish C, et al. Long-acting injectable ART and PrEP among women in six cities across the United States: a qualitative analysis of who would benefit the most. AIDS Behav. 2022;26(4):1260\u20139. https:\/\/doi.org\/10.1007\/s10461-021-03483-7.","journal-title":"AIDS Behav"},{"issue":"3","key":"1373_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","volume":"84","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, Parish CL, Kinnard EN, et al. Multisite study of women living with HIV\u2019s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84(3):263\u201370. https:\/\/doi.org\/10.1097\/QAI.0000000000002337.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"1373_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/HIV.70057","volume":"26","author":"K Ring","year":"2025","unstructured":"Ring K, Elias A, Devonald M, Smuk M, Orkin C. Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: a systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV. HIV Med. 2025;26(8):1267\u201388. https:\/\/doi.org\/10.1111\/HIV.70057.","journal-title":"HIV Med"},{"issue":"12","key":"1373_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2165\/00002018-200528120-00003","volume":"28","author":"R Clark","year":"2005","unstructured":"Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28(12):1075\u201383. https:\/\/doi.org\/10.2165\/00002018-200528120-00003.","journal-title":"Drug Saf"},{"key":"1373_CR33","doi-asserted-by":"publisher","first-page":"103246","DOI":"10.1016\/j.eclinm.2025.103246","volume":"84","author":"Z Fang","year":"2025","unstructured":"Fang Z, Povshedna T, Patterson R, et al. Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysis. eClinicalMedicine. 2025;84:103246. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103246.","journal-title":"eClinicalMedicine"},{"issue":"6","key":"1373_CR34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/QAD.0000000000001408","volume":"31","author":"CM Puskas","year":"2017","unstructured":"Puskas CM, Kaida A, Miller CL, et al. The adherence gap: a longitudinal examination of men\u2019s and women\u2019s antiretroviral therapy adherence in British Columbia, 2000-2014. AIDS. 2017;31(6):827\u201333. https:\/\/doi.org\/10.1097\/QAD.0000000000001408.","journal-title":"AIDS"},{"issue":"1","key":"1373_CR35","doi-asserted-by":"publisher","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","volume":"13","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Gorgolas M, et al. Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a phase\u00a0II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS ONE. 2018;13(1):e0190487. https:\/\/doi.org\/10.1371\/journal.pone.0190487.","journal-title":"PLoS ONE"},{"issue":"12","key":"1373_CR36","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/S10461-020-02918-X","volume":"24","author":"A Mantsios","year":"2020","unstructured":"Mantsios A, Murray M, Karver TS, et al. Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of Phase\u00a03 trials. AIDS Behav. 2020;24(12):3473\u201381. https:\/\/doi.org\/10.1007\/S10461-020-02918-X.","journal-title":"AIDS Behav"},{"issue":"8","key":"1373_CR37","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1080\/13691058.2020.1752397","volume":"23","author":"A Mantsios","year":"2021","unstructured":"Mantsios A, Murray M, Karver TS, et al. \u201cI feel empowered\u201d: women\u2019s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. Cult Health Sex. 2021;23(8):1066\u201378. https:\/\/doi.org\/10.1080\/13691058.2020.1752397.","journal-title":"Cult Health Sex"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01373-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01373-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01373-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:06:19Z","timestamp":1783616779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01373-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01373-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ana Gonz\u00e1lez-Cord\u00f3n has received honoraria for lectures or AB, consulting fees, and\/or research grants from Gilead Sciences, J&J, Merck Sharp & Dohme and ViiV Healthcare, and travel support from Gilead Sciences, and ViiV Healthcare, outside the submitted work. J\u00falia Calvo has received honoraria for lectures or AB, and travel support from ViiV Healthcare, Gilead Sciences and Janssen, outside the submitted work. Maria Mart\u00ednez\u2011Rebollar has received honoraria for lectures or AB from Gilead Sciences, ViiV Healthcare and J&J, has received honoraria for leadership role from Gilead Sciences, and travel support from Gilead Sciences, outside the submitted work. Ivan Chivite has received honoraria for lectures, consulting fees, and research grants from Gilead Sciences, Janssen (J&J), Merck Sharp & Dohme, and ViiV Healthcare, as well as travel support from Gilead Sciences and ViiV Healthcare, outside the submitted work. Alexy Inciarte has received research funding from Gilead, Janssen, and GSK and has served on AB for Almirall, Pfizer, AbbVie, and Bayer, outside the submitted work. Juan Ambrosioni has received research funding from ViiV Healthcare and Gilead Sciences, has participated in AB for ViiV, Gilead Sciences, MSD and J&J, has received personal compensation for presentations from ViiV, Gilead Sciences, MSD and J&J, has participated in DSMB for HIPRA and Grifols. Juan Ambrosioni is an Editorial Board member of\n                      Infectious Diseases and Therapy.\n                      Juan Ambrosioni was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Lorena de la Mora has received honoraria for lectures or AB and\/or research grants, and travel support from ViiV Healthcare, Gilead Sciences and Janssen, outside the submitted work. Alberto Foncillas has received honoraria for lectures or AB and\/or research grants, and travel support from ViiV Healthcare, Gilead Sciences and Janssen, outside the submitted work. Abiu Sempere has received honoraria for lectures and\/or research grants and travel support from Gilead Sciences, ViiV Healthcare and MSD, outside the submitted work. Jos\u00e9 Luis Blanco has received honoraria for lectures or AB and\/or research grants, and travel support from Gilead Sciences, ViiV Healthcare, and MSD, outside the submitted work. Esteban Martinez has received honoraria for lectures or AB and\/or research grants from Gilead Sciences, ViiV Healthcare, and MSD, outside the submitted work, and has held unpaid leadership roles as Past President of EACS and as President of NEAT ID. Jose M. Miro has received consulting honoraria and\/or research grants from Angelini, Basilea, Contrafect, Cubist, Genentech, Gilead Sciences, Janssen, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work. Jose M. Miro received a personal 80:20 research grant from Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017\u201326, unrelated to the present study. Josep Mallolas has received honoraria for lectures from Gilead Sciences, ViiV Healthcare, J&J and MSD, outside the submitted work. Montserrat Laguno has received research funding from ViiV Healthcare and Gilead Sciences, has participated in AB for J&J, has received personal compensation for presentations from ViiV Healthcare, Gilead Sciences, MSD and J&J, and travel support from Gilead Sciences, outside the submitted work. Berta Torres has received honoraria for lectures or AB, consulting fees, and\/or research grants from Gilead Sciences, Janssen, Merck Sharp & Dohme and ViiV Healthcare, and travel support from Gilead Sciences,\u00a0ViiV Healthcare, and MSD, outside the submitted work. Leire Berrocal, Maite Le\u00f3n-Fabo, Paula Arreba, Pilar Callau, Roger Llobet, Elisa de Lazzari have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The protocol was approved by the local Ethics Committee (protocol number HCB\/2022\/0770) and was conducted in accordance with the Good Clinical Practice Guidelines and Declaration of Helsinki. All participants provided written informed consent before enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}